Resumen Curricular de los Profesores. Jesse Boehm

Transcription

1 Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub in the scientific planning and organization of program projects, collaborations, and activities. His research efforts focus on developing systematic approaches to map the function of genes that are mutated in tumors. Previously, Boehm worked for three and a half years as a research scientist in the Broad Cancer Program. In this role he managed several large, collaborative research efforts that spanned multiple platforms, programs and initiatives at the Broad Institute and Dana-Farber Cancer Institute. These included the generation of functional genomics tools for the community as well as the deployment of these tools in systematic, high-throughput experiments to determine the function of elements in the cancer genome. Boehm received his B.S. in biology from MIT and his Ph.D. from Harvard University, Division of Medical Sciences. For his graduate studies, he worked in the laboratory of William Hahn at the Dana- Farber Cancer Institute, where he developed and utilized new experimental models of cellular transformation, the process by which cells become cancerous. 1

2 Jose C. Florez Jose C. Florez, M.D., Ph.D. is an Assistant in Medicine (Endocrine Division) at the Massachusetts General Hospital, an Associate Professor at Harvard Medical School, and an Associate Member at the Broad Institute, where he is active in the Program in Medical and Population Genetics and the Broad Metabolism Initiative. He and his group have contributed to the performance and analysis of genome-wide association studies in type 2 diabetes and related traits, in the Diabetes Genetics Initiative (formed by the Broad Institute, Lund University and Novartis), the Framingham Heart Study, and other international consortia such as MAGIC, GENIE and DIAGRAM. He leads the genetic research efforts of the Diabetes Prevention Program, where the effects of genetic variants on the development of diabetes can be examined prospectively, and their impact on specific behavioral and pharmacological preventive interventions can be assessed. He is the Principal Investigator of the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR MGH), and also conducts other pharmacogenetic studies at MGH. He is an author on 100+ original publications and 30+ reviews/book chapters. In addition to his research and teaching duties, he is clinically active in the MGH Diabetes Center, the Endocrine inpatient consult service, and the Down Syndrome Program. He serves on the Editorial Boards for Diabetes and for Human Genetics, as well as the Advisory Board for Diabetologia; he is also the Editor-in-Chief for Current Diabetes Reports. He is the recipient of the MGH Physician Scientist Development Award, a Doris Duke Charitable Foundation Clinical Scientist Development Award, the MGH Department of Medicine Stephen Krane Award, the MGH Research Scholars Award, and the 2010 Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government on science and engineering professionals in the early stages of their independent research careers. 2

3 Brian Hubbard Brian Hubbard is director of the Therapeutics Projects Group (TPG) at the Broad Institute of MIT and Harvard. Under his leadership, and drawing on the Broad s multiple programs and platforms, his group aspires to transform the process of drug discovery and the treatment of human disease by developing and applying novel drug discovery technologies; targeting novel classes of protein targets, generally viewed as undruggable ; targeting novel mechanisms emerging from studies of human biology; and working in an open, collaborative environment to establish proofs of concept. Hubbard brings extensive knowledge of drug discovery and development. Before coming to the Broad, he was Senior Director of Cardiovascular Diseases at Merck, where he was responsible for strategy and execution of research. His focus was primarily atherosclerosis research. While at Merck, Hubbard was also part of a core team that developed a strategic plan for restructuring basic research in the pharmaceutical industry. Prior to his work at Merck, Hubbard was Director of Cardiovascular and Metabolism Research at Novartis Institutes for Biomedical Research and did research into metabolic diseases and obesity at Millennium Pharmaceuticals. Hubbard received his B.S. in chemistry from The College of William and Mary and a Ph.D. in chemistry from the University of Illinois Champaign-Urbana. He did postdoctoral research in biochemistry and antibiotics at Harvard Medical School. 3

4 Nikhil Wagle Nikhil Wagle is a medical oncologist at Dana-Farber Cancer Institute, an instructor at Harvard Medical School, and an associate member of the Broad Institute. As a member of the Broad s Cancer Program, Wagle studies cancer genomics and precision (or personalized ) cancer medicine. Using genomic profiling, Wagle comprehensively characterizes patient tumor samples in order to better understand the molecular roots of cancer, characterize mechanisms of therapeutic resistance, and identify actionable genomic alterations to aid with clinical decision-making. In 2011, he published a novel approach for precision cancer medicine using targeted sequencing to profile more than 150 clinically-relevant cancer genes from archival tumor samples. Wagle is currently helping to lead the effort to implement a prospective sequencing program to guide clinical management of cancer patients, known as CanSeq, at Dana-Farber Cancer Institute, Brigham and Women s Hospital, and the Broad Institute. Wagle s research also focuses on characterization of patients with cancer who develop resistance to targeted therapies. He previously identified a novel mechanism of resistance to the targeted therapy vemurafenib in metastatic melanoma. He continues to study mechanisms of resistance in metastatic melanoma, as well as resistance to targeted therapies in breast cancer, lung cancer, and other solid tumors to identify novel ways to treat refractory advanced cancer. Wagle has recently focused his efforts on understanding the genomic mechanisms of extraordinary responses to cancer therapies by studying so-called exceptional responders patients with exquisite sensitivity and/or unexpected durable responses to targeted agents. Wagle has presented his work at the annual meetings of the American Association of Cancer Research and the American Society of Clinical Oncology. He is a recipient of the prestigious Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology, and the 2013 Landon Foundation-AACR INNOVATOR Award for Research in Personalized Cancer Medicine. His work has been published in the Journal of Clinical Oncology, Nature Medicine, and Cancer Discovery. Wagle received his undergraduate degree in Biochemical Sciences from Harvard College and his M.D. from Harvard Medical School in the Harvard-MIT Division of Health Sciences and Technology. He completed his residency training in Internal Medicine at Brigham and Women's Hospital, where he also served as Chief Medical Resident, and completed his fellowship training in Hematology/Oncology in the Dana-Farber/Partners Cancer Care program. 4

5 Geoffrey Walford Dr. Geoffrey Walford is an endocrinologist at Massachusetts General Hospital and an Instructor in Medicine at Harvard Medical School (both in Boston, Massachusetts, USA). He graduated from Dartmouth Medical School and completed his internal medicine training at Brigham and Women s Hospital and fellowship in Endocrinology, Diabetes, and Metabolism at Massachusetts General Hospital. Dr. Walford joined the laboratory of Dr. Jose C. Florez in His primary research interest is in the application of genetic and metabolomic technologies in humans to improve the prediction, prevention, and treatment of type 2 diabetes and other metabolic diseases. 5

Teaching Medicine and Teaching Science: Is there a difference? From MD to PhD (Clinical Researcher) Ines Vaz Luis September 2013 Disclosures I have no disclosures But. I have a WARNING: This talk is largely

SEQUENCING INITIATIVE SUOMI (SISU) SYMPOSIUM SPEAKERS August 26, 2014 Professor Aarno Palotie Professor Aarno Palotie is the Research Director of the Human Genomics program at the Finnish Institute for

A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

Master of Science in BIOINFORMATICS > information > insight > innovation The Program Master of Science in Bioinformatics The College of Science at Northeastern University is committed to delivering cutting-edge

HARVARD MEDICAL SCHOOL CANCER BIOLOGY & THERAPEUTICS PROGRAM CBT A joint initiative of the Harvard Medical School Office of Global Education and the Qatar Biomedical Research Institute (QBRI) 2015-2016

David Altshuler, M.D., Ph.D. Deputy Director and Chief Academic Officer, Broad Institute of Harvard and MIT Cambridge, Massachusetts, U.S. Endocrinologist and human geneticist David Altshuler is a professor

Anforderungen der Life-Science Industrie an die Hochschulen Hans Widmer Novartis Institutes for BioMedical Research There s nothing more extraordinary than a normal life 2 What does industry expect from

HEMATOLOGY/ONCOLOGY FACULTY POSITIONS IN PRECISION CANCER MEDICINE The Division of Hematology/Oncology, Department of Internal Medicine, and the University of Michigan Comprehensive Cancer Center (UMCCC)

Future Directions in Cancer Research What does is mean for medical physicists and AAPM? John D. Hazle, Ph.D., FAAPM, FACR President-elect American Association of Physicists in Medicine Professor and Chairman

A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

Graduate Fellowships Preparing the leaders of tomorrow school of medicine The Campaign for Washington University Together, we change lives. Washington University educates and trains outstanding scientists

MASTER OF SCIENCE BIOTECHNOLOGY Networked for Success. Networked for Industry. Networked for Life. Bouvé College of Health Sciences College of Science Northeastern s Biotechnology Masters program synthesizes

Profile of Biomedical Research and Biotechnology Commercialization Boston-Worcester-Lawrence Consolidated Metropolitan Statistical Area Overview and History of Biotechnology in Boston Along with San Francisco,

Ph.D. in Bioinformatics and Computational Biology Degree Requirements Credits Students pursuing the doctoral degree in BCB must complete a minimum of 90 credits of relevant work beyond the bachelor s degree;

The for DUKE MEDICINE Decades of hard work by dedicated physicians and scientists, along with capable and often inspired leadership, have placed the Duke School of Medicine among the nation s best. Now,

CURRICULUM FOR RESEARCH POSTGRADUATE PROGRAMS Master of Philosophy (MPhil) and Doctor of Philosophy (PhD) Programs in Life Science Curriculum for Master of Philosophy (MPhil) Program in Life Science The

PHYSIOLOGY THE STUDY OF LIFE, and how genes, cells, tissues, and organisms function. What is PHYSIOLOGY? Physiologists teach and mentor students in both the classroom and laboratory. Physiologists apply

Ushering in a new era of cancer medicine Center is ushering in a new era of cancer medicine. Progress that could not even be imagined a decade ago is now being realized in our laboratories and our clinics.

Master of Science in Biomedical Sciences Faculty of Medicine Good health is our greatest treasure. Understanding the human body, healthy and diseased, is the stepping stone to finding tools to improving

skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th

COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,

(BSGP) The Biology of Human Disease medicine.osu.edu/bsgp Welcome from BSGP Leadership Thank you for your interest in the at The Ohio State University Wexner Medical Center. Our goal is to train talented,

Ph.D Programs at Near East University Faculty of Pharmacy Ph.D Programs at Near East University, Faculty of Pharmacy NEU Faculty of Pharmacy offers advanced training and education leading toward Ph.D degree.

To prepare students for careers in the pharmaceutical, biotechnical, consumer product and health care industries. Types of work include laboratory, regulatory oversight, engineering, economics, marketing,

10 this time, it s Personal In what is an exciting era in the evolution of oncology treatment, this special feature by Deborah J. Ausman explores how Next-Generation Sequencing and Convergent Informatics

Novartis Institutes for Biomedical Research and Massachusetts College of Pharmacy and Health Sciences, Worcester/Manchester PharmD Postdoctoral Fellowship Program Introduction Fellowship training in the

Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aaps.org/forstudents How Do I Know If a Career in the Pharmaceutical Sciences is Right

MD/PhD MISSION OBJECTIVES GOALS Mission & Objectives Overarching Objective: Train physician-scientists to be an integral component of the healthcare system, now and into the future. Expectations for Graduates:

Research and Development in the Czech Republic Mr. Jiri Krechl Head of R&D Support Department CZECHINVEST Investment and Business Development Agency Ministry of Industry and Trade CzechInvest Investment

Below are various organizations that offer research opportunities for medical students. Please go to the websites listed for detailed information regarding the organization as well as the research program.

The Healing Power of Data The Healing Power of Data A Message from the Dean and Vice President for Health Sciences Imagine living in a world in which: a mobile device predicts when you are at high risk

Elective Options for MS in Clinical and Translational Sciences Program NOTE: ALL ELECTIVES MUST BE GRADUATE LEVEL COURSES AND APPROVED BY A MS CTS PROGRAM DIRECTOR IN ORDER TO RECEIVE CREDIT TOWARDS MCTS

The Physiology Undergraduate Major in the University of Arizona College of Medicine Tucson, AZ Erik J. Henriksen, Ph.D. Professor Director, Physiology Undergraduate Program Department of Physiology ejhenrik@u.arizona.edu

Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research

MD-PhD: Is it Right for Me? Training & Career Paths What is a physician-scientist? Men and women who are physicians and investigators (and mentors and teachers and inventors and ) Spend most of their professional

University of Medicine and Dentistry of New Jersey (UMDNJ) Dual-Degree Program between the UMDNJ Graduate School of Biomedical Sciences (GSBS) And the UMDNJ School of Public Health (SPH) Leading to the:

Is a Career in the Pharmaceutical Sciences Right for Me? Check out our online Student Center to find out more: www.aapspharmaceutica.com/students How do I know if a career in the pharmaceutical sciences

Entering a Clinical Trial Is It Right for You? Paula Chandoha, Chandoha Productions About This Program THIS AUDIOVISUAL PROGRAM AND BOOKLET WERE produced by Dana-Farber Cancer Institute in collaboration

Graduate Studies in Biomedical Sciences The graduate program in Biomedical Sciences is designed to provide a multidisciplinary educational and training environment that will prepare them for independent

Clinical and Health Policy Innovation Seminar for Hematologists. An Executive seminar for Senior Clinicians From May 6 th to 10 th, 2013 INTRODUCTION The Universitat Internacional de Catalunya (UIC) and

Masters of Science in Clinical (MSCR) Curriculum Goal/Objective of the MSCR The MSCR program is an interdisciplinary research degree program housed within the Department of Epidemiology in the School of

Degree Programmes Bachelor Master PhD/Dr. rer. nat. International Graduate School in Molecular Medicine Ulm IGradU Funded by the Excellence Initiative of the German federal and state governments www.uni-ulm.de/mm

isbtc/sitc Exceptional Service Award Recipients Awarded October 3, 2010 for distinguished leadership, continued contribution, and consummate dedication which fostered the growth and success of isbtc. Michael

Biological Sciences Major The Biological Sciences address many of the most important and fundamental questions about our world: What is life? How does our brain produce our ideas and emotions? What are

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes

UPBM CURRICULAR BROCHURE Undergraduate Program in Biology and Medicine Contents Academic Year 2015-16 About the Undergraduate Program in Biology and Medicine...pg. 1 Undergraduate Majors...pg. 2-3 Getting